Download Files:
Atuveciclib
$280 – $800
Products Details
Product Description
– Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM[1].
Web ID
– HY-12871B
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C18H18FN5O2S
References
– [1]Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793.
CAS Number
– 2923012-24-0
Molecular Weight
– 387.43
Compound Purity
– 99.80
SMILES
– N=[S@](CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : ≥ 128.5 mg/mL
Target
– CDK
Isoform
– CDK1;CDK2;CDK3;CDK5;CDK9
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
